{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:55:00Z","timestamp":1785477300803,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Somatropin treatment is indicated in a variety of disorders including growth hormone (GH) deficiency, Prader\u2013Willi and Turner syndrome, chronic renal insufficiency and others. To date, almost all studies have been limited to single GH products, and no independent registry across indications and somatropin products was ever established.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The present investigator-initiated registry named INSIGHTS-GHT aims to provide comprehensive information on various aspects of somatropin treatment in Germany in approved indications within routine clinical practice: drug utilization, effectiveness (including real final height, body composition), tolerability, quality of life, other patient related outcomes (PRO), and health economic variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Registry (prospective observational study) in specialised pediatric and adult endocrinology centres in Germany. Patients of any age are eligible for documentation, if they are on ongoing or newly initiated treatment with any approved somatropin or somatropin-related product within the labelling, available for long term follow-up documentation, and if they provided informed consent. Subjects may switch, discontinue\/interrupt or initiate somatropin products at any time. They are followed up for at least 3\u00a0years (minimal study duration). Documentation is planned once or twice per year to record somatropin utilisation (product, dosing), other medications, laboratory status (glucose, lipids, GH function including stimulation tests, IGF-I, IGFBP3), if applicable, pubertal development, auxological parameters, body composition and bone age. Patient reported outcome (PRO) measures include, but are not limited to, Short Form 12 in adults and adolescents aged 14\u00a0years and over. Safety reporting includes adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The registry documents children and adults in one joint registry, includes, at present, patients in Germany and allows documentation of patients on all approved somatropin and other growth hormone preparations. It will allow to describe the transition of subjects from adolescence to adulthood (treatment and height), to describe switches between somatotropin preparations, to perform responder analyses, and to analyse differences and similarities of somatropin utilization (by age group, sex, setting, and PRO instrument). INSIGHTS-GHT offers a broad, comprehensive research platform to assess multiple relevant aspects of somatropin treatment and outcomes (including the transition of subjects from adolescence to adulthood), allows the documentation of all GH products including long-acting GH preparations after their introduction, and will evaluate the data independently of funders.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> BfArM Nr. NIS7492, DRKS registry DRKS00027394.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02716-3","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T13:07:55Z","timestamp":1683724075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol)"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-7790","authenticated-orcid":false,"given":"Dirk","family":"Schnabel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilonka","family":"Kreitschmann-Andermahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Strasburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pittrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Pausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Woelfle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the INSIGHTS-GHT Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"2716_CR1","unstructured":"Head J. Growth hormonce deficiency. National Organisation for Rare Disease (NORD). Internet: https:\/\/rarediseases.org\/rare-diseases\/growth-hormone-deficiency\/ Accessed on 16 Jan 2023."},{"key":"2716_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09594-1","author":"NA Tritos","year":"2020","unstructured":"Tritos NA, Biller BMK. Current concepts of the diagnosis of adult growth hormone deficiency. Rev Endocr Metab Disord. 2020. https:\/\/doi.org\/10.1007\/s11154-020-09594-1.","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2716_CR3","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1210\/jc.2011-0179","volume":"96","author":"ME Molitch","year":"2011","unstructured":"Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587\u2013609.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2716_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2042018813479644","volume":"4","author":"R Pfaffle","year":"2013","unstructured":"Pfaffle R, Schwab KO, Marginean O, Walczak M, Szalecki M, Schuck E, et al. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope((R)) in children requiring growth hormone treatment. Ther Adv Endocrinol Metab. 2013;4(1):3\u201311.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"2716_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13052-016-0302-3","volume":"42","author":"L Iughetti","year":"2016","unstructured":"Iughetti L, Tornese G, Street ME, Napoli F, Giavoli C, Antoniazzi F, et al. Long-term safety and efficacy of Omnitrope(R), a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study. Ital J Pediatr. 2016;42(1):93.","journal-title":"Ital J Pediatr"},{"key":"2716_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01331-4","author":"L Iughetti","year":"2020","unstructured":"Iughetti L, Antoniazzi F, Giavoli C, Bona G, Aversa T, Greggio NA, et al. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort. J Endocrinol Investig. 2020. https:\/\/doi.org\/10.1007\/s40618-020-01331-4.","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"2716_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000508190","volume":"93","author":"R Pfaffle","year":"2020","unstructured":"Pfaffle R, Bidlingmaier M, Kreitschmann-Andermahr I, Land C, Partsch CJ, Schwab KO, et al. Safety and effectiveness of Omnitrope(R), a biosimilar recombinant human growth hormone: more than 10 years\u2019 experience from the PATRO children study. Horm Res Paediatr. 2020;93(3):154\u201363.","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"2716_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s40618-017-0664-4","volume":"40","author":"D Ferone","year":"2017","unstructured":"Ferone D, Profka E, Gasco V, Ambrosio MR, Colao A, Di Somma C, et al. Erratum to: long-term safety and efficacy of Omnitrope((R)) in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. J Endocrinol Invest. 2017;40(6):679\u201381.","journal-title":"J Endocrinol Invest"},{"key":"2716_CR9","doi-asserted-by":"publisher","first-page":"204201882094337","DOI":"10.1177\/2042018820943377","volume":"11","author":"P Beck-Peccoz","year":"2020","unstructured":"Beck-Peccoz P, Hoybye C, Murray RD, Simsek S, Zabransky M, Zouater H, et al. Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope((R))): data from the PATRO Adults study. Ther Adv Endocrinol Metab. 2020;11:2042018820943377.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2716_CR10","unstructured":"Committee for Medicinal Products for Human Use (CHMP). CPMP\/ICH\/377\/95. ICH Topic E 2 A. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5. Effective June 1995. Internet: https:\/\/www.ema.europa.eu\/en\/ich-e2a-clinical-safety-data-management-definitions-standards-expedited-reporting. Accessed 16 Jan 2023."},{"key":"2716_CR11","unstructured":"Bullinger M. Assessment of health related quality of life with the SF-36 Health Survey. Die Rehabilit. 1996;35(3): XVII-XXVII, quiz XXVII-XXIX."},{"issue":"3","key":"2716_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220\u201333.","journal-title":"Med Care"},{"key":"2716_CR13","unstructured":"Deutsche Gesellschaft f\u00fcr Epidemiologie (GGEpi). Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). Aktualisierung September 2018. Internet: https:\/\/www.dgepi.de\/assets\/Leitlinien-und-Empfehlungen\/Leitlinien_fuer_Gute_Epidemiologische_Praxis_GEP_vom_September_2018.pdf. Accessed 4 Jan 2021."},{"key":"2716_CR14","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). Gemeinsame Empfehlungen des Bundesinstituts f\u00fcr Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zu Anwendungsbeobachtungen nach \u00a7 67 Absatz 6 Arzneimittelgesetz und zur Anzeige von nichtinterventionellen Unbedenklichkeitspr\u00fcfungen nach \u00a7 63f Arzneimittelgesetz vom 20. 2019. Internet: https:\/\/www.bfarm.de. Accessed 16 Jan 2023."},{"key":"2716_CR15","unstructured":"Agency for Healthcare Research and Quality (AHRQ). Registries for evaluating patient outcomes: a user's guide. In: RE Gliklich, MB Leavy, NA Dreyer, Senior Editors. AHRQ Publication No.19(29)-EHC020. Rockville, MD, USA. Forth edition 2020. Internet: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562575\/. Accessed 16 Jan 2023."},{"key":"2716_CR16","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1210\/clinem\/dgac517","volume":"107","author":"M Maghnie","year":"2022","unstructured":"Maghnie M, Ranke MB, Geffner ME, Vlachopapadopoulou E, Ibanez L, Carlsson M, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort. J Clin Endocrinol Metab. 2022;107:3287\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2716_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/ebmed-2017-110885","volume":"23","author":"IJ Onakpoya","year":"2018","unstructured":"Onakpoya IJ. Rare adverse events in clinical trials: understanding the rule of three. BMJ Evid Based Med. 2018;23(1):6.","journal-title":"BMJ Evid Based Med"},{"issue":"7005","key":"2716_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/bmj.311.7005.619","volume":"311","author":"E Eypasch","year":"1995","unstructured":"Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995;311(7005):619\u201320.","journal-title":"BMJ"},{"key":"2716_CR19","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). MedDRA (Medical Dictionary for Regulatory Activities). Internet: https:\/\/www.meddra.org\/mssoweb\/index.htm. Accessed on 16 Jan 2023."},{"issue":"7624","key":"2716_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"},{"key":"2716_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.18","volume":"3","author":"MD Wilkinson","year":"2016","unstructured":"Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016;3: 160018.","journal-title":"Sci Data"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02716-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02716-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02716-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T13:12:24Z","timestamp":1683724344000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02716-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2716"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02716-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"20 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The registry materials (protocol, patient information and informed consent form (ICF), and other required documents) were approved by the primary ethics committee (Ethics Committee of the Physician Chamber Saxony EK-BR-8\/22-1 dated 26 January 2022). Any site that joins the registry has to provide additional ethics approval, if required by their local institutions. Protocol amendments, if any, will be subject to the same requirements as the original protocol. Written informed consent is a prerequisite for patients to be eligible for documentation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DS: received consultant and\/or speaker fees from Ascendis, Biomarin, Kyowa Kirin, Merck\/Serono, Novo Nordisk, Pfizer, Sandoz\/Novartis. CS: received consultancy fees from NovoNordisk, Sandoz-Hexal\/Novartis, Ascendis, Pfizer, Consilient Health, Crinetics and Ipsen. DP: received consultancy fees from Amgen, Aspen, Biogen, Daiichi Sankyo, Sanofi-Genzyme, Sandoz\/Novartis, MSD and Zambon. CP: has no competing interests. JW: received consultant and\/or speaker fees from Ascendis, Biomarin, Merck\/Serono, Novo Nordisk, Pfizer, Sandoz\/Novartis. IKA: received consultant and speaker fees from Sandoz\/Novartis and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}